title: [Increase of interleukin-2 soluble receptors in multiple sclerosis: preliminary study in 26 patients].
abstract: Serum samples were analysed for interleukin-2 receptors levels (sIL-2R) in 26 patients with definite multiple sclerosis as defined by Poser and col. Three groups of patients form the basis of this study: group I, with 14 patients with clinical evidence of active disease; group II, with 12 patients with clinically stable multiple sclerosis; and group III, with 8 patients with other neurological diseases. Blood was collected by venipuncture and centrifuged. All samples were stored at -20 degrees C until testing. The assay used monoclonal antibodies against epitopes of interleukin-2 receptors. In the wells of a microtiter plate coated with anti-soluble interleukin-2 receptors (Immunotech SA) samples to be measured or standards are incubated in the presence of a second monoclonal antibody conjugated with alkaline phosphatase. The amount of bound enzyme-conjugate is measured by adding a chromogenic substrate. The intensity of the resulting colour is proportional to the sIL-2R concentration present in the sample. Increased serum levels of sIL-2R were found in 7 of 14 patients with active multiple sclerosis (50%), in only 1 of the 12 patients with clinically stable multiple sclerosis and in none of the patients with other neurological diseases.
authors: Disciplina de Neurologia, Faculdade de Ciências Médicas da Santa Casa de São Paulo.
authors: C P
authors: CP
authors: Tilbery
authors: E
authors: E
authors: Felipe
authors: I M
authors: IM
authors: Mota
authors: M A
authors: MA
authors: Scheinberg
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000032:analysis* / Q000502:physiology; D013601:T-Lymphocytes / Q000378:metabolism
chemical_list: D015375:Receptors, Interleukin-2
vernacular_title: Aumento dos receptores solúveis da interleucina-2 na esclerose múltipla: estudo preliminar em 26 pacientes.